Latest News
Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA
Genentech, a member of the Roche Group, today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type […]
Read More ›Annual SMA Conference Registration Continues to Grow!
The 2020 Annual SMA Conference registration numbers are growing quickly! We expect the 2020 conference – which includes both the Family Conference and the Research & Clinical Care Meeting – […]
Read More ›Community Statement from Scholar Rock Regarding SRK-015
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today highlighted key accomplishments of the past year […]
Read More ›Cure SMA and Biogen to Co-Host Webinar on DEVOTE Clinical Trial – Register Today!
On Tuesday, February 4th, at 11am CST (9am PST/10am MST/12pm EST) Biogen and Cure SMA will co-host a webinar for the SMA community. During the webinar, you’ll hear from Biogen […]
Read More ›Cure SMA’s New Year Letter for 2020
Dear SMA Community, We are excited to be kicking off a new year and a new decade full of promise for the SMA community. Over the past week on our […]
Read More ›Community Spotlight: The Forcier Family
Kara and Ryan Forcier, of Stillwater, Minn., were on a rollercoaster almost immediately after the birth of their son, Zachary. Zachary was born with skin lesions that turned into blood […]
Read More ›